SCHEMBL1684679

SCHEMBL1684679

Cc1nc2ccc(Cl)cn2c1-c1csc(Nc2cccc(Cl)c2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.62
ALDH1A1 P00352 4/20 0.62
KDM4E B2RXH2 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
LMNA P02545 3/20 0.62
HTT P42858 3/20 0.62
GAA P10253 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
NR2F2 P24468 1/20 0.62
CACNA1B Q00975 1/20 0.59
APBA1 Q02410 1/20 0.59
KLF5 Q13887 1/20 0.59
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
HPGD P15428 2/20 0.53
ALOX12 P18054 1/20 0.53
CDK2 P24941 2/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PIM1 P11309 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040668 0.99 MAPT (0.61) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL1684839 0.94 MAPT (0.72) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
Bromide SCHEMBL18040717 0.93 MAPT (0.70) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL1684542 0.91 MAPT (0.59) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL2353272 0.91 CACNA1B (0.73) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL1684633 0.91 KDM4E (0.59) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL1684756 0.90 MAPT (0.61) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
Bromide SCHEMBL18040773 0.90 KDM4E (0.58) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
Bromide SCHEMBL18040792 0.90 CACNA1B (0.72) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
Bromide SCHEMBL18040720 0.89 MAPT (0.63) MAPTALDH1A1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885ALDH1A1 2357/4885KDM4E 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.